Three large NGOs signalled concern on Monday that Big Pharma is seeking to impact reforms of the EU drug framework by persuading the European Commission to introduce new incentives to support innovation amid growing global trade tensions.
The Association of European Cancer Leagues (ECL), the European Consumer Organisation (BEUC), and the International Association of Mutual Benefit Societies (AIM) also warned in a joint statement addressed to the EU executive that the rising costs of innovative medicines continue to place them out of reach for many patients, deepening health inequalities across Europe.
